Mesoblast Ltd

NASDAQ:MESOUnited States

Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.

Contact Information

Headquarters

L 38 55 Collins StMELBOURNE, VIC, Australia 3000

Phone

---

Fax

---

Executives

Non-Executive Independent Chairman of the Board

Jane Bell

Chief Executive Officer, Executive Director

Silviu Itescu

Non-Executive Independent Vice Chairman of the Board

William Burns

Interim Chief Financial Officer

Andrew Chaponnel

Senior Vice President, Head - Translational Research

Fiona See